BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Perspective Therapeutics (AMEX: CATX) and maintained a price target of $14 for the stock. This endorsement reflects confidence in the company's performance and potential growth.